[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123). 2. Results of a multicenter clinical trial of CN 3123 in infections of the kidneys and urinary tract].
During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) results from 925 treated cases of bacterial infections of the urinary organs were documented. The analysis revealed the following conclusions: 1. On the basis of all the assessable cases, there was no clinical effect in less than 10% of patients and no bacteriological effect in only 13% of patients. The therapeutic response was clinically good in 76% and bacteriologically good in 68% of the patients. The rest of the patients showed a fair clinical response, that is to say they showed a definite improvement in the clinical picture, or some bacteriological response, i.e. a definite reduction in the organism counts or, in mixed infections, not all the strains of pathogen were eradicated. 2. There was a higher success rate in acute urinary tract infections which had not previously been treated than in chronic or previously treated cases. 3. The therapeutic results in the principal indications were as follows: Pyelonephritis: 73.9% good and 16.5% fair effect clinically; 63.6% good and 21.6% some effect bacteriologically. Pyelitis: 81.1% good and 18.9% fair effect clinically; 70.4% good and 25.9% some effect bacteriologically. Cystitis: 81.3% good and 8.6% fair effect clinically; 68.9% good and 17.6% some effect bacteriologically. Postoperative urinary tract infections: 98% good effect clinically and bacteriologically. Infections of the urinary organs (not specified in more detail): 71.8% good and 16.1% fair effect clinically; 65.0% good and 18.8% some effect bacteriologically.